Response by Sattar et al to Letters Regarding Article, "Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks"

被引：2
|
作者：
Sattar, Naveed [1 ]
Rawshani, Araz [2 ]
Franzen, Stefan [3 ,4 ]
机构：
[1] Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland
[2] Univ Gothenburg, Dept Mol & Clin Med, Inst Med, Gothenburg, Sweden
[3] Univ Gothenburg, Hlth Metr Unit, Sahlgrenska Acad, Gothenburg, Sweden
[4] Swedish Natl Diabet Register, Vastra Gotalandsreg, Gothenburg, Sweden
来源：
CIRCULATION | 2019年 / 140卷 / 16期
关键词：
D O I：
10.1161/CIRCULATIONAHA.119.042457
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E724 / E725
页数：2
相关论文
共 50 条
  • [1] Letter by Wang et al Regarding Article, "Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks"
    Wang, Daxin
    Chen, Tian
    Yang, Xinquan
    CIRCULATION, 2019, 140 (16) : E720 - E721
  • [2] Letter by Wang and Xu Regarding Article, "Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks"
    Wang, Junfeng
    Xu, Yang
    CIRCULATION, 2019, 140 (16) : E722 - E723
  • [3] Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks Findings From the Swedish National Diabetes Registry
    Sattar, Naveed
    Rawshani, Araz
    Franzen, Stefan
    Rawshani, Aidin
    Svensson, Ann-Marie
    Rosengren, Annika
    McGuire, Darren K.
    Eliasson, Bjorn
    Gudbjornsdottir, Soffia
    CIRCULATION, 2019, 139 (19) : 2228 - 2237
  • [4] Response by Kato et al to Letter Regarding Article, "Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus"
    Kato, Eri T.
    Sabatine, Marc S.
    Wiviott, Stephen D.
    CIRCULATION, 2019, 140 (18) : E740 - E741
  • [5] Response by Wanner et al to Letters Regarding Article, "Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease"
    Wanner, Christoph
    von Eynatten, Maximilian
    Zinman, Bernard
    CIRCULATION, 2018, 138 (08) : 850 - 851
  • [6] Letter by Elghazaly et al Regarding Article, "Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus"
    Elghazaly, Hussein
    Hajiev, Saur
    Singh, Parminder
    CIRCULATION, 2019, 140 (18) : E738 - E739
  • [7] Response by Zinman et al to Letter Regarding Article, "Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk"
    Zinman, Bernard
    Inzucchi, Silvio E.
    Diener, Hans Christoph
    STROKE, 2017, 48 (09) : E256 - E257
  • [8] Letter by Tampaki et al Regarding Article, "Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk"
    Tampaki, Ekaterini Christina
    Tampakis, Athanasios
    Gurke, Lorenz
    STROKE, 2017, 48 (09) : E255 - E255
  • [9] Response by Sorensen et al to Letters Regarding Article, "Prediabetes and Type 2 Diabetes Are Associated With Generalized Microvascular Dysfunction: The Maastricht Study"
    Sorensen, Ben M.
    Houben, Alfons J. H. M.
    Martens, Remy J. H.
    Stehouwer, Coen D. A.
    CIRCULATION, 2017, 135 (14) : E862 - E863
  • [10] Response by Hu et al to Letters Regarding Article, "Platelets Express Activated P2Y12 Receptor in Patients With Diabetes Mellitus"
    Hu, Liang
    Qi, Zhiyong
    Zhang, Si
    Luo, Xinping
    Kunapuli, Satya P.
    Ye, Hongying
    Ding, Zhongren
    CIRCULATION, 2018, 137 (17) : 1877 - 1878
12345